Lexicon Pharmaceuticals
LXRX
109 hedge funds and large institutions have $846M invested in Lexicon Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 35 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
7% more funds holding
Funds holding: 102 → 109 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 35
24% less capital invested
Capital invested by funds: $1.12B → $846M (-$274M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$8.52M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.15M |
| 3 |
JG
Jefferies Group
New York
|
+$4.8M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.22M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.55M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.23M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$1.16M |
LXRX Hedge Fund Activity: Q4 2013 in Review
109 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2013, worth a combined $846M — down 24% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LXRX positions and 7 closed out — a net gain of 8 holders — while 30 added to existing stakes and 35 trimmed.
The largest buyer was UBS AM, adding an estimated $8.52M. The largest seller was T. Rowe Price Associates, cutting an estimated $16.7M.
- 109 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2013, up from 102 in Q3 2013.
- Funds reported $846M of Lexicon Pharmaceuticals stock for Q4 2013, down 24% quarter-over-quarter.
- 15 funds opened new Lexicon Pharmaceuticals positions in Q4 2013 and 7 closed out, a net change of +8 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2013 was UBS AM, an estimated $8.52M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2013.